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Multidrug resistance (MDR) in tuberculosis (TB) threatens the global management of the disease, which is already a leading cause of infectious mortality worldwide, with an estimated 450,000 MDR-TB cases reported in 2012 ([@B1]). Approximately 10% of MDR-TB cases (those resistant to rifampin and isoniazid) are further defined as extensively drug resistant (XDR)-TB, due to their resistance to second-line drugs, fluoroquinolones and injectable aminoglycosides ([@B2]). Long turnaround times (2 to 4 weeks) for phenotypic drug susceptibility testing (DST) (due to the fastidious nature of the organism) can hamper the appropriate treatment of XDR-TB by delaying access to antibiotic susceptibility data ([@B3]). Next-generation sequencing (NGS) can highlight resistance in a timely manner in order to effectively manage treatment and minimize further transmission of resistant strains ([@B4][@B5][@B6]).

The first Irish XDR-TB strain was isolated in the Irish Mycobacteria Reference Laboratory (IMRL) in 2005 (IEXDR1) ([@B7], [@B8]). First-line DST was completed within 3 weeks (found to be streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide resistant), second-line DST within 5 weeks (found to be amikacin, clarithromycin, ciprofloxacin, and rifabutin resistant, as well as capreomycin, clofazimine, and prothionamide susceptible), and the remainder within 14 weeks (found to be *para*-aminosalicylate sodium \[PAS\] resistant and ethionamide and cycloserine susceptible).

In 2014, NGS was performed to provide further molecular characterization of IEXDR1 (lineage 2 or Beijing strain). Genomic DNA was sequenced using an Illumina MiSeq. Paired-end reads were mapped to the *Mycobacterium tuberculosis* H37Rv reference genome (accession no. AL123456.3) using the Burrows-Wheeler Aligner ([@B9]). This yielded a mapped-read depth of 196-fold, covering 97.6% of the H37Rv genome. A consensus sequence was called using the SAMtools mpileup command ([@B10]). The IMAGE algorithm was employed to extend contigs and close gaps in the assembly, producing a final draft assembly of 4,340,174 bp, consisting of 109 contigs ([@B11]). Single-nucleotide polymorphism (SNP) analysis was performed using Geneious R7 (version 7.1.5; Biomatters); 1,492 SNPs were detected in the assembled genome with respect to the genome of H37Rv, of which 810 were nonsynonymous (depth of coverage, ≥20-fold \[average, 276\]; variant frequency, ≥95%).

Nonsynonymous mutations were identified in genes Rv0667/*rpoB* (H526Y) and Rv1908c/*katG* (S315T). There is strong correlation between substitutions in *rpoB* (H526Y) and *katG* (S315T) and phenotypic resistance to rifampin and isoniazid, respectively ([@B4], [@B12]). High-confidence SNPs were also found for fluoroquinolone resistance in gene Rv0006 (*gyrA*) (D94A) and aminoglycoside resistance in MTB000019/*rrs* (a1401g) ([@B12]). This is consistent with the XDR phenotype of IEXDR1. Other high-confidence mutations found in IEXDR1 for ethambutol (Rv3795/*embB* \[M306V\]) and streptomycin (Rv0682/*rpsL* \[K43R\]) correlate with its drug resistance profile ([@B13], [@B14]). SNPs that may confer resistance to pyrazinamide (Rv2043c/*pncA* \[G132C\]) and PAS (Rv3764c/*thyA* \[Q97R\]) were also identified, although their specificities and sensitivities are not as well defined (<http://www.broadinstitute.org/annotation/genome/mtb_drug_resistance.1/DirectedSequencingHome.html>).

Previously described phylogenetically informative polymorphisms (Rv1908c/*katG* \[R463L\], Rv2629 \[D64A\], Rv3794/*embA* \[C76C, TGC/TGT\] and \[Q38Q, CAA/CAG\], Rv1630/*rpsA* \[R212R, CGA/CGC\], Rv3919c/*gidB* \[E92D\], and Rv0486/*mshA* \[A187V\]) confirm the presence of a Beijing strain ([@B15]).

In summary, using NGS, this isolate was confirmed to be XDR-TB in a considerably shorter turnaround time than that for conventional DST. This underlines the potential of NGS in the diagnostic laboratory, especially for MDR- and XDR-TB cases.

Nucleotide sequence accession number. {#h1}
-------------------------------------

This whole-genome sequencing project has been deposited in the European Nucleotide Archive under the accession no. [CCJS00000000](http://www.ebi.ac.uk/ena/data/view/CCJS00000000).
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